SB203580, a p38 inhibitor, improved cardiac function but worsened lung injury and survival during escherichia coli pneumonia in mice

Journal of Trauma - Injury, Infection and Critical Care

Volumn 68, Issue 6, 2010, Pages 1317-1327

  Su, Junwu ^a,b   Cui, Xizhong ^a   Li, Yan ^a   Mani, Haresh ^c   Ferreyra, Gabriela A ^a   Danner, Robert L ^a   Hsu, Lewis L ^d   Fitz, Yvonne ^a   Eichacker, Peter Q ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Cardiopulmonary dysfunction; P38 MAP kinase inhibitor; Pneumonia; Sepsis; Treatment

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CEFTRIAXONE; MITOGEN ACTIVATED PROTEIN KINASE P38; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; ESCHERICHIA COLI PNEUMONIA; HEART FUNCTION; HEART OUTPUT; LOW DRUG DOSE; LUNG INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-BACTERIAL AGENTS; CARDIAC OUTPUT; ECHOCARDIOGRAPHY; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI INFECTIONS; FLUID THERAPY; IMIDAZOLES; LIPOPOLYSACCHARIDES; LUNG INJURY; MICE; PLACEBOS; PNEUMONIA; PROPORTIONAL HAZARDS MODELS; PYRIDINES; SURVIVAL RATE;

EID: 77953734976     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/TA.0b013e3181bb9cd3     Document Type: Article

References (52)

1. Hoesel LM, Gao H, Ward PA. New insights into cellular mechanisms during sepsis. Immunol Res. 2006;34:133-141.
2. Grund EM, Kagan D, Tran CA, et al. Tumor necrosis factor-alpha regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor kappaB in human endometriotic epithelial cells. Mol Pharmacol. 2008;73:1394-1404.
3. Jeyaseelan S, Young SK, Fessler MB, et al. Toll/IL-1 receptor domaincontaining adaptor inducing IFN-beta (TRIF)-mediated signaling contributes to innate immune responses in the lung during Escherichia coli pneumonia. J Immunol. 2007;178:3153-3160.
4. Zhang YL, Dong C. MAP kinases in immune responses. Cell Mol Immunol. 2005;2:20-27.
5. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol. 1998; 274:R577-R595.
6. Togbe D, Schnyder-Candrian S, Schnyder B, et al. Toll-like receptor and tumour necrosis factor dependent endotoxin-induced acute lung injury. Int J Exp Pathol. 2007;88:387-391.
7. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov. 2003;2:717-726.
8. Asaduzzaman M, Wang Y, Thorlacius H. Critical role of p38 mitogenactivated protein kinase signaling in septic lung injury. Crit Care Med. 2008;36:482-488.
9. Liu S, Feng G, Wang GL, Liu GJ. p38MAPK inhibition attenuates LPS-induced acute lung injury involvement of NF-kappaB pathway. Eur J Pharmacol. 2008;584:159-165.
10. Nash SP, Heuertz RM. Blockade of p38 map kinase inhibits complementinduced acute lung injury in a murine model. Int Immunol Pharmacol. 2005;5:1870-1880.
11. Nick JA, Young SK, Brown KK, et al. Role of p38 mitogen-activated protein kinase in a murine model of pulmonary inflammation. J Immunol. 2000;164:2151-2159.
12. Peng T, Lu X, Lei M, Moe GW, Feng Q. Inhibition of p38 MAPK decreases myocardial TNF-alpha expression and improves myocardial function and survival in endotoxemia. Cardiovasc Res. 2003;59:893-900.
13. Underwood DC, Osborn RR, Bochnowicz S, et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol. 2000;279: L895-L902.
14. Wang M, Sankula R, Tsai BM, et al. p38 MAPK mediates myocardial proinflammatory cytokine production and endotoxin-induced contractile suppression. Shock. 2004;21:170-174.
15. Branger J, van den Blink B, Weijer S, et al. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol. 2002;168:4070-4077.
16. Fijen JW, Tulleken JE, Kobold AC, et al. Inhibition of p38 mitogenactivated protein kinase: dose-dependent suppression of leukocyte and endothelial response after endotoxin challenge in humans. Crit Care Med. 2002;30:841-845.
17. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther. 1996;279:1453-1461.
18. Yoshinari D, Takeyoshi I, Koibuchi Y, et al. Effects of a dual inhibitor of tumor necrosis factor-alpha and interleukin-1 on lipopolysaccharideinduced lung injury in rats: involvement of the p38 mitogen-activated protein kinase pathway. Crit Care Med. 2001;29:628-634.
19. Doyle SE, O'Connell RM, Miranda GA, et al. Toll-like receptors induce a phagocytic gene program through p38. J Exp Med. 2004;199:81-90.
20. Henneke P, Takeuchi O, Malley R, et al. Cellular activation, phagocytosis, and bactericidal activity against group B streptococcus involve parallel myeloid differentiation factor 88-dependent and independent signaling pathways. J Immunol. 2002;169:3970-3977.
21. Laroux FS, Romero X, Wetzler L, Engel P, Terhorst C. Cutting edge: MyD88 controls phagocyte NADPH oxidase function and killing of gram-negative bacteria. J Immunol. 2005;175:5596-5600.
22. Schmeck B, Zahlten J, Moog K, et al. Streptococcus pneumoniaeinduced p38 MAPK-dependent phosphorylation of RelA at the interleukin-8 promotor. J Biol Chem. 2004;279:53241-53247.
23. Toledo-Pereyra LH. Critical role of p38 mitogen protein kinase in sepsis. Crit Care Med. 2008;36:636-637.
24. Vikstrom E, Magnusson KE, Pivoriunas A. The Pseudomonas aeruginosa quorum-sensing molecule N-(3-oxododecanoyl)-L-homoserine lactone stimulates phagocytic activity in human macrophages through the p38 MAPK pathway. Microbes Infect. 2005;7:1512-1518.
25. Song GY, Chung CS, Jarrar D, Chaudry IH, Ayala A. Evolution of an immune suppressive macrophage phenotype as a product of p38 MAPK activation in polymicrobial sepsis. Shock. 2001;15:42-48.
26. Tong L, Pav S, White DM, et al. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat Struct Biol. 1997;4:311-316.
27. Wang Z, Canagarajah BJ, Boehm JC, et al. Structural basis of inhibitor selectivity in MAP kinases. Structure. 1998;6:1117-1128.
28. Kellum JA, Kong L, Fink MP, et al; GenIMS Investigators. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med. 2007;167:1655-1663.
29. Li Y, Cui X, Li X, et al. Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. coli pneumonia model: risk and corticosteroids in sepsis. Intensive Care Med. 2008;34:568-577.
30. Zeni F, Parent C, Correa R, et al. ICAM-1 and CD11b inhibition worsen outcome in rats with E. coli pneumonia. J Appl Physiol. 1999;87:299-307.
31. Cui X, Moayeri M, Li Y, et al. Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats. Am J Physiol Regul Integr Comp Physiol. 2004;286:R699-R709.
32. Haley M, Parent C, Cui X, et al. Neutrophil inhibition with L-selectindirected MAb improves or worsens survival dependent on the route but not severity of infection in a rat sepsis model. J Appl Physiol. 2005;98: 2155-2162.
33. Yao L, Berman JW, Factor SM, Lowy FD. Correlation of histopathologic and bacteriologic changes with cytokine expression in an experimental murine model of bacteremic Staphylococcus aureus infection. Infect Immun. 1997;65:3889-3895.
34. Solomon SB, Cui X, Gerstenberger E, et al. Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection. J Infect Dis. 2006;193:634-644.
35. Kan W, Zhao KS, Jiang Y, et al. Lung, spleen, and kidney are the major places for inducible nitric oxide synthase expression in endotoxic shock: role of p38 mitogen-activated protein kinase in signal transduction of inducible nitric oxide synthase expression. Shock. 2004;21:281-287.
36. Hirano S, Rees RS, Yancy SL, et al. Endothelial barrier dysfunction caused by LPS correlates with phosphorylation of HSP27 in vivo. Cell Biol Toxicol. 2004;20:1-14.
37. Niwa K, Inanami O, Ohta T, Ito S, Karino T, Kuwabara M. p38 MAPK and Ca2 contribute to hydrogen peroxide-induced increase of permeability in vascular endothelial cells but ERK does not. Free Radic Res. 2001;35:519-527.
38. Lopez A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004;32:21-30.
39. Greenberger MJ, Strieter RM, Kunkel SL, et al. Neutralization of macrophage inflammatory protein-2 attenuates neutrophil recruitment and bacterial clearance in murine Klebsiella pneumonia. J Infect Dis. 1996;173:159-165.
40. van Faassen H, KuoLee R, Harris G, Zhao X, Conlan JW, Chen W. Neutrophils play an important role in host resistance to respiratory infection with Acinetobacter baumannii in mice. Infect Immun. 2007; 75:5597-5608.
41. Nick JA, Young SK, Arndt PG, et al. Selective suppression of neutrophil accumulation in ongoing pulmonary inflammation by systemic inhibition of p38 mitogen-activated protein kinase. J Immunol. 2002;169: 5260-5269.
42. Adib-Conquy M, Moine P, Asehnoune K, et al. Toll-like receptormediated tumor necrosis factor and interleukin-10 production differ during systemic inflammation. Am J Respir Crit Care Med. 2003;168: 158-164.
43. Ma W, Lim W, Gee K, et al. The p38 mitogen-activated kinase pathway regulates the human interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages. J Biol Chem. 2001;276:13664-13674.
44. Elenkov IJ, Iezzoni DG, Daly A, Harris AG, Chrousos GP. Cytokine dysregulation, inflammation and well-being. Neuroimmunomodulation. 2005;12:255-269.
45. Choi JC, Jung JW, Kwak HW, et al. Granulocyte macrophage-colony stimulating factor (GM-CSF) augments acute lung injury via its neutrophil priming effects. J Korean Med Sci. 2008;23:288-295.
46. Dhanireddy S, Altemeier WA, Matute-Bello G, et al. Mechanical ventilation induces inflammation, lung injury, and extra-pulmonary organ dysfunction in experimental pneumonia. Lab Invest. 2006;86:790-799.
47. Koprak S, Staruch MJ, Dumont FJ. A specific inhibitor of the p38 mitogen activated protein kinase affects differentially the production of various cytokines by activated human T cells: dependence on CD28 signaling and preferential inhibition of IL-10 production. Cell Immunol. 1999;192:87-95.
48. Song GY, Chung CS, Chaudry IH, Ayala A. MAPK p38 antagonism as a novel method of inhibiting lymphoid immune suppression in polymicrobial sepsis. Am J Physiol Cell Physiol. 2001;281:C662-C669.
49. Boldt S, Kolch W. Targeting MAPK signalling: Prometheus' fire or Pandora's box? Curr Pharm Des. 2004;10:1885-1905.
50. Schindler JF, Monahan JB, Smith WG. p38 pathway kinases as antiinflammatory drug targets. J Dent Res. 2007;86:800-811.
51. Beardmore VA, Hinton HJ, Eftychi C, et al. Generation and characterization of p38beta (MAPK11) gene-targeted mice. Mol Cell Biol. 2005; 25:10454-10464.
52. Wrobleski ST, Doweyko AM. Structural comparison of p38 inhibitorprotein complexes: a review of recent p38 inhibitors having unique binding interactions. Curr Top Med Chem. 2005;5:1005-1016.